| CAS NO: | 83730-53-4 |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 222.31 |
| Cas No. | 83730-53-4 |
| Formula | C8H18N2O3S |
| Solubility | ≤50mg/ml in PBS, pH 7.2 |
| Chemical Name | (2S)-2-amino-4-(butylsulfonimidoyl)butanoic acid |
| Canonical SMILES | O=S(CCCC)(CC[C@@H](C(O)=O)N)=N |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
L-Buthionine-(S,R)-sulfoximine is a cell-permeable, irreversible inhibitor of g-glutamylcysteine synthetase[1].
In ZAZ and M14 melanoma cell line, L-Buthionine-(S,R)-sulfoximine (50 μM) treatment for 48 hr results in a 95% decrease in GSH levels, and a 60% decrease in GST enzyme activity. GST-mu protein and mRNA levels are significantly reduced in both cell lines[1].
L-Buthionine-(S,R)-sulfoximine (BSO) treatment significantly increases the frequency of DNA deletions and reduces concentrations of GSH and cysteine. BSO (20 mM) treatment results in a 40% increase in DNA deletion frequency, a 70% decrease in GSH, and a 55% decrease in cysteine levels[2].
References：
[1]. Fruehauf J P, et al. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase. Pigment Cell Res, 1997, 10(4): 236-49.
[2]. Reliene R, et al. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis, 2006, 27(2): 240-4.
m.cnreagent.com